The US Food and Drug Administration has tagged Jubilant Pharmova Ltd's active pharmaceutical ingredient manufacturing facility at Nanjangud as "voluntary action indicated", according to an exchange filing.
The Nanjangud facility had received eight observations from the regulatory body as a result of an examination between December 5 and 13.
According to this inspection and the USFDA's designation of "voluntary action indicated," the Nanjangud facility complies with current good manufacturing standards, according to Jubilant Pharmova.
The shares of Jubilant Pharmova closed 3.7% higher at ₹315.75 on NSE.
RBI's Liquidity Boost To Aid Rate Cut Transmission, Fitch Sees Easing Funding Conditions In 2025
Medical Counselling For MBBS & BDS Courses In Tamil Nadu To Begin July 30; Merit List Out On July 25
Urvashi Rautela Flaunts ₹6 Crore Diamond Watch At Wimbledon 2025 (See Photos)
Now Pay Parking Fees Via FASTag in Mumbai As BMC Cracks Down On Fake Parking Attendants
